Latest News about SRPT
Recent news which mentions SRPT
FDA AdComm Narrowly Supports Approval Of Sarepta's Gene Therapy For Rare Neuromuscular Disorder
May 15, 2023
Tickers
SRPT
From Benzinga
2 Supercharged Growth Stocks to Buy Right Now
May 14, 2023
From Motley Fool
FDA Staff Raises Issues For Sarepta's Duchenne Gene Therapy Data, Analyst Says Issues Known, Expects Positive Vote
May 10, 2023
Tickers
SRPT
From Benzinga
From Benzinga
From Benzinga
Tickers
SRPT
From Motley Fool
From Benzinga
Drug manufacturer Catalent’s stock tumbles 25% after profit warning and CFO departure
April 14, 2023
From MarketWatch
Sarepta stock hit by renewed uncertainty about gene therapy treatment for rare disease
April 13, 2023
From MarketWatch
Analysts Says Stat News Article Adds Uncertainty To Sarepta's SRP-9001, But Offers Buying Opportunity Around The Weakness
April 13, 2023
Tickers
SRPT
From Benzinga
Why Is Merck (MRK) Stock Up Today?
April 13, 2023
From InvestorPlace
Why Is BigBear.ai (BBAI) Stock Down 5% Today?
April 13, 2023
From InvestorPlace
Why Is Sarepta Therapeutics (SRPT) Stock Down 12% Today?
April 13, 2023
From InvestorPlace
From Benzinga
2 Top Growth Stocks That Could Soar This Spring
April 06, 2023
From Motley Fool
From Benzinga
The 3 Best CRISPR Stocks to Buy Now Before They Skyrocket
March 25, 2023
From InvestorPlace
3 Up-and-Coming Growth Stocks to Buy Right Now
March 25, 2023
From Motley Fool
TD Cowen Maintains Outperform Rating for Sarepta Therapeutics: Here's What You Need To Know
March 22, 2023
Tickers
SRPT
From Benzinga
Accelerated Approval For Gene Therapies - US Health Regulator Looks To Improve Process
March 21, 2023
Tickers
SRPT
From Benzinga
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.